Eli Lilly and Company (LLY)

$1,003.46 -40.67 (-3.90%)
Market Cap 980.51B
Revenue (ttm) 45.04B
Net Income (ttm) 10.59B
EPS (ttm) N/A
PE Ratio 46.57
Forward PE 30.81
Profit Margin 23.51%
Debt to Equity Ratio 1.71
Volume 5,483,921
Avg Vol 3,083,990
Day's Range N/A - N/A
Shares Out 945.38M
Stochastic %K 44%
Beta 0.35
Analysts Strong Sell
Price Target $1,163.88

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncolog...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
nvda_wins_at_the_end
nvda_wins_at_the_end Feb. 3 at 11:46 PM
$NVO will it go higher if $LLY er is bad.
0 · Reply
DickStockman
DickStockman Feb. 3 at 11:38 PM
$NVO $LLY
0 · Reply
PharmaBro2
PharmaBro2 Feb. 3 at 11:25 PM
$LLY 800 or 1100??
1 · Reply
Bazzzigar
Bazzzigar Feb. 3 at 11:09 PM
$LLY below $800?
0 · Reply
Ro_Patel
Ro_Patel Feb. 3 at 10:44 PM
Medicare drug price negotiations to include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer & arthritis. These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions. The negotiated prices for the 15 drugs chosen this year will take effect in 2028. About 1.8M beneficiaries used these medications b/n Nov 2024 & Oct 2025, and they accted for about $27B in Medicare Part B & D spending Note: 14 of the drugs, Medicare revs exposed to the negotiations represents only 0% to 3% of the companies’ worldwide 2027 sales. $GILD Biktarvy, a once-daily pill that treats HIV, draws significant sales from Medicare, representing around 8% of Gilead’s est'd global FY27 revs $LLY $ABBV $GSK $PFE
0 · Reply
Bazzzigar
Bazzzigar Feb. 3 at 10:37 PM
$LLY better be out
1 · Reply
CashisKing_
CashisKing_ Feb. 3 at 10:28 PM
$LLY $IXHL maybe just maybe?
0 · Reply
Jten10
Jten10 Feb. 3 at 10:16 PM
$NVO $VKTX is literally the only acquisition that keeps $NVO in the same league as $LLY.
1 · Reply
judgeyoung2
judgeyoung2 Feb. 3 at 9:33 PM
$LLY Lilly is not Novo, $1250 coming
4 · Reply
PickAlpha
PickAlpha Feb. 3 at 9:15 PM
PickAlpha Midday- Novo Nordisk guided for 2026 adjusted sales and adjusted operating profit (constant exchange rates) to fall 5%–13%, citing lower realized prices (especially US), intensifying GLP-1 competition, and semaglutide patent expiries in some ex-US markets. Ozempic / Wegovy are the key franchises, and the stock reaction was violent (US-listed shares down ~12% in the session cited by Reuters).  Tickers: $NVO $LLY $XLV Our view is this is a clean GLP-1 reset: volume can grow, but price is rolling over (policy + competition). If net pricing stabilizes (or the oral Wegovy ramp shows true incremental demand) by the next 1–2 prints, this is tradable “buy-the-panic”; if pricing keeps deteriorating and guidance has to be cut again, the multiple still has downside.
1 · Reply
Latest News on LLY
Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 7 hours ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR NVO PFE VKTX

Obesity market sales potential tightens as Novo and Lilly enter new era

Feb 2, 2026, 6:07 AM EST - 1 day ago

Obesity market sales potential tightens as Novo and Lilly enter new era

NVO

Top 15 High-Growth Dividend Stocks For February 2026

Feb 1, 2026, 10:22 PM EST - 1 day ago

Top 15 High-Growth Dividend Stocks For February 2026

ACN ADP AVGO BMI CDW DPZ ELV

Jim Cramer on what is driving Eli Lilly's stock right now

Jan 30, 2026, 7:46 PM EST - 4 days ago

Jim Cramer on what is driving Eli Lilly's stock right now

Cramer's week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data

Jan 30, 2026, 6:17 PM EST - 4 days ago

Cramer's week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data

AMZN GOOG GOOGL

Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch

Jan 30, 2026, 3:44 PM EST - 4 days ago

Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch

Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push

Jan 30, 2026, 11:04 AM EST - 4 days ago

Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push

Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections

Jan 30, 2026, 11:02 AM EST - 4 days ago

Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

Jan 30, 2026, 11:00 AM EST - 4 days ago

Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility

Pennsylvania Wins Bid for Eli Lilly Weight-Loss Drug Factory

Jan 30, 2026, 11:00 AM EST - 4 days ago

Pennsylvania Wins Bid for Eli Lilly Weight-Loss Drug Factory

Why Dividend Stocks Are Essential For What Comes Next

Jan 30, 2026, 7:30 AM EST - 4 days ago

Why Dividend Stocks Are Essential For What Comes Next

AM CAG EPD ET KMI MPLX O

Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive

Jan 29, 2026, 4:51 PM EST - 5 days ago

Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive

Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion

Jan 29, 2026, 1:58 PM EST - 5 days ago

Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion

Trump says Eli Lilly to build six US plants

Jan 29, 2026, 1:05 PM EST - 5 days ago

Trump says Eli Lilly to build six US plants

Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies

Jan 29, 2026, 6:31 AM EST - 5 days ago

Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies

Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless

Jan 28, 2026, 7:02 AM EST - 6 days ago

Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless

Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows

Jan 28, 2026, 6:07 AM EST - 6 days ago

Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows

NVO

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 7 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

ABBV PFE

Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog

Jan 25, 2026, 6:26 AM EST - 9 days ago

Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog

NVO

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

Jan 23, 2026, 7:00 AM EST - 11 days ago

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

NVO

Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

Jan 21, 2026, 10:00 AM EST - 13 days ago

Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot

Jan 21, 2026, 9:14 AM EST - 13 days ago

Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot

Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)

Jan 21, 2026, 9:06 AM EST - 13 days ago

Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)

Polen Focus Growth Portfolio  Q4 2025 Performance, Attribution & Portfolio Activity

Jan 21, 2026, 3:53 AM EST - 13 days ago

Polen Focus Growth Portfolio  Q4 2025 Performance, Attribution & Portfolio Activity

AAPL ABT AMZN GOOG GOOGL ISRG IWB

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

Jan 20, 2026, 7:45 AM EST - 14 days ago

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

Jan 20, 2026, 6:01 AM EST - 14 days ago

Abivax CEO dismisses 'noise' around rumored Eli Lilly bid

ABVX

Eli Lilly, Nvidia team up in a $1B AI innovation lab.

Jan 17, 2026, 3:30 PM EST - 17 days ago

Eli Lilly, Nvidia team up in a $1B AI innovation lab.

NVDA

Our Top 10 High Growth Dividend Stocks - January 2026

Jan 17, 2026, 8:05 AM EST - 17 days ago

Our Top 10 High Growth Dividend Stocks - January 2026

APH ASML AU BK CIB CINF COKE

Buy The Dip In LLY Stock?

Jan 16, 2026, 9:50 AM EST - 18 days ago

Buy The Dip In LLY Stock?

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Jan 15, 2026, 11:35 AM EST - 19 days ago

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

AZN GEHC RNA

MoneyShow's Best Investment Ideas For 2026: Part 4

Jan 14, 2026, 3:50 PM EST - 20 days ago

MoneyShow's Best Investment Ideas For 2026: Part 4

AGM EPD EXE GEV HVT

Eli Lilly and Company (LLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 7:56 PM EST - 21 days ago

Eli Lilly and Company (LLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook

Jan 13, 2026, 10:21 AM EST - 21 days ago

Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook

Expect a Busy Year in Obesity Drugs as New Pills Hit the Market

Jan 12, 2026, 4:21 PM EST - 22 days ago

Expect a Busy Year in Obesity Drugs as New Pills Hit the Market

NVO

Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly

Jan 12, 2026, 3:51 PM EST - 22 days ago

Nvidia to Invest $1 Billion in AI Drug Lab With Eli Lilly

NVDA

Eli Lilly CFO on $1 billion Nvidia investment

Jan 12, 2026, 2:00 PM EST - 22 days ago

Eli Lilly CFO on $1 billion Nvidia investment

NVDA

Eli Lilly CFO on $1 Billion AI Drug Lab Investment

Jan 12, 2026, 12:04 PM EST - 22 days ago

Eli Lilly CFO on $1 Billion AI Drug Lab Investment

Lilly says it's confident in weight-loss pill supply ahead of U.S. approval

Jan 12, 2026, 11:07 AM EST - 22 days ago

Lilly says it's confident in weight-loss pill supply ahead of U.S. approval

Nvidia Partners With Eli Lilly on AI Drug Laboratory

Jan 12, 2026, 10:28 AM EST - 22 days ago

Nvidia Partners With Eli Lilly on AI Drug Laboratory

NVDA

Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab

Jan 12, 2026, 10:04 AM EST - 22 days ago

Nvidia, Eli Lilly to spend $1 billion over five years on joint research lab

NVDA

France has had no request for investment approval in biotech Abivax - official

Jan 12, 2026, 9:49 AM EST - 22 days ago

France has had no request for investment approval in biotech Abivax - official

ABVX

Abivax stock rockets 30% on Eli Lilly takeover speculation

Jan 12, 2026, 9:32 AM EST - 22 days ago

Abivax stock rockets 30% on Eli Lilly takeover speculation

ABVX

Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid

Jan 12, 2026, 5:03 AM EST - 22 days ago

Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid

ABVX

Abivax shares soar 23% as media report reignites M&A chatter

Jan 12, 2026, 4:38 AM EST - 22 days ago

Abivax shares soar 23% as media report reignites M&A chatter

ABVX

2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

Jan 10, 2026, 8:00 AM EST - 24 days ago

2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market

NVO

Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham

Jan 9, 2026, 6:22 PM EST - 25 days ago

Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham

NVO

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

Jan 9, 2026, 12:58 PM EST - 25 days ago

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

AKTS

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 25 days ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN AZN BMY MRK NVO PFE

nvda_wins_at_the_end
nvda_wins_at_the_end Feb. 3 at 11:46 PM
$NVO will it go higher if $LLY er is bad.
0 · Reply
DickStockman
DickStockman Feb. 3 at 11:38 PM
$NVO $LLY
0 · Reply
PharmaBro2
PharmaBro2 Feb. 3 at 11:25 PM
$LLY 800 or 1100??
1 · Reply
Bazzzigar
Bazzzigar Feb. 3 at 11:09 PM
$LLY below $800?
0 · Reply
Ro_Patel
Ro_Patel Feb. 3 at 10:44 PM
Medicare drug price negotiations to include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer & arthritis. These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions. The negotiated prices for the 15 drugs chosen this year will take effect in 2028. About 1.8M beneficiaries used these medications b/n Nov 2024 & Oct 2025, and they accted for about $27B in Medicare Part B & D spending Note: 14 of the drugs, Medicare revs exposed to the negotiations represents only 0% to 3% of the companies’ worldwide 2027 sales. $GILD Biktarvy, a once-daily pill that treats HIV, draws significant sales from Medicare, representing around 8% of Gilead’s est'd global FY27 revs $LLY $ABBV $GSK $PFE
0 · Reply
Bazzzigar
Bazzzigar Feb. 3 at 10:37 PM
$LLY better be out
1 · Reply
CashisKing_
CashisKing_ Feb. 3 at 10:28 PM
$LLY $IXHL maybe just maybe?
0 · Reply
Jten10
Jten10 Feb. 3 at 10:16 PM
$NVO $VKTX is literally the only acquisition that keeps $NVO in the same league as $LLY.
1 · Reply
judgeyoung2
judgeyoung2 Feb. 3 at 9:33 PM
$LLY Lilly is not Novo, $1250 coming
4 · Reply
PickAlpha
PickAlpha Feb. 3 at 9:15 PM
PickAlpha Midday- Novo Nordisk guided for 2026 adjusted sales and adjusted operating profit (constant exchange rates) to fall 5%–13%, citing lower realized prices (especially US), intensifying GLP-1 competition, and semaglutide patent expiries in some ex-US markets. Ozempic / Wegovy are the key franchises, and the stock reaction was violent (US-listed shares down ~12% in the session cited by Reuters).  Tickers: $NVO $LLY $XLV Our view is this is a clean GLP-1 reset: volume can grow, but price is rolling over (policy + competition). If net pricing stabilizes (or the oral Wegovy ramp shows true incremental demand) by the next 1–2 prints, this is tradable “buy-the-panic”; if pricing keeps deteriorating and guidance has to be cut again, the multiple still has downside.
1 · Reply
ChicagoMan
ChicagoMan Feb. 3 at 9:05 PM
$LLY 1,150 tomorrow on an earnings beat...
2 · Reply
topstockalerts
topstockalerts Feb. 3 at 8:56 PM
Novo Nordisk shares plummeted 14% on Tuesday, marking a "Black Tuesday" for the Danish pharma giant. Despite beating 2025 revenue expectations with DKK 309.1 billion, the company shocked investors by forecasting a 5% to 13% sales decline for 2026—a sharp reversal from its previous double-digit growth. Key Drivers of the Slump The "Trump Effect" & MFN Policy: Under the Trump administration’s "Most Favored Nation" (MFN) pricing actions, Novo has been forced to slash prices to match the lowest rates in developed nations. This includes a landmark deal to sell Ozempic/Wegovy to Medicare for just $245/month. Insurance Erosion: U.S. sales are expected to crater as state Medicaid programs and private insurers scale back coverage for GLP-1 weight-loss medications due to high costs. The "Lilly" Factor: Rival Eli Lilly continues to exert massive pressure with its tirzepatide treatments. $NVO $LLY
0 · Reply
TrustButVerifi
TrustButVerifi Feb. 3 at 8:21 PM
$VKTX https://youtu.be/YkADj0TPrJA?t=122 $TSLA $SNDK $LLY $META
0 · Reply
Dr_Stoxx
Dr_Stoxx Feb. 3 at 8:17 PM
$LLY not so good into earnings
1 · Reply
minotaurr
minotaurr Feb. 3 at 8:15 PM
$LLY let’s beat
1 · Reply
Ray89c
Ray89c Feb. 3 at 8:12 PM
$ALUR all partnerships slowly building up. Waiting for the big day. FDA approval soon 🤞. As they proving combination therapy with $LLY hope they buyout allur. $PZE $NVO $RXRX
0 · Reply
senseidragon
senseidragon Feb. 3 at 8:09 PM
@Olddrache volume for $LLY $SMCI $ENPH ?cheers
0 · Reply
explover
explover Feb. 3 at 8:08 PM
Not like $ALT is an obesity stock if we are not counting Corinne's opinion, but $NVO admitted that $LLY is taking their ground and their revenue and guidance are to be disclosed tomorrow. May be up for a macro surprise for the "obesity sector". I mean tirzepatide is still the best. M
0 · Reply
StocktwitsNews
StocktwitsNews Feb. 3 at 7:57 PM
VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report $VKTX $NVO $LLY https://stocktwits.com/news/equity/markets/vktx-shares-garner-retail-attention-ahead-of-q4-earnings-report/cZb02YuR4mN
0 · Reply
PharmaBro2
PharmaBro2 Feb. 3 at 7:52 PM
$LLY 800 tomorrow. no money for insurance. no money for drugs
0 · Reply
DonCorleone77
DonCorleone77 Feb. 3 at 7:35 PM
$LLY $ABBV $UBER $BSX $JCI Some notable companies reporting before tomorrow's open, with earnings consensus estimates: - Eli Lilly (LLY), consensus $6.93 - Abbvie (ABBV), consensus $2.65 - Uber (UBER), consensus 78c - Boston Scientific (BSX), consensus 78c - Johnson Controls (JCI), consensus 84c - Yum Brands (YUM), consensus $1.76 - GE Healthcare (GEHC), consensus $1.40 - Cognizant (CTSH), consensus $1.32 - Foxa (FOXA), consensus 52c - Equifax (EFX), consensus $2.05 - Fortive (FTV), consensus 84c
0 · Reply
fuegie
fuegie Feb. 3 at 7:30 PM
$NVO this is not good. When $LLY get their pill FDA approved and if they take the market by storm, Novo will definitely be down even bigger.
0 · Reply